180 related articles for article (PubMed ID: 15730857)
1. Introduction of OX40 ligand into lymphoma cells elicits anti-lymphoma immunity in vivo.
Kaneko H; Hori T; Yanagita S; Kadowaki N; Uchiyama T
Exp Hematol; 2005 Mar; 33(3):336-43. PubMed ID: 15730857
[TBL] [Abstract][Full Text] [Related]
2. CD28-independent costimulation of T cells by OX40 ligand and CD70 on activated B cells.
Akiba H; Oshima H; Takeda K; Atsuta M; Nakano H; Nakajima A; Nohara C; Yagita H; Okumura K
J Immunol; 1999 Jun; 162(12):7058-66. PubMed ID: 10358148
[TBL] [Abstract][Full Text] [Related]
3. Characterization of rat OX40 ligand by monoclonal antibody.
Satake Y; Akiba H; Takeda K; Atsuta M; Yagita H; Okumura K
Biochem Biophys Res Commun; 2000 Apr; 270(3):1041-8. PubMed ID: 10772947
[TBL] [Abstract][Full Text] [Related]
4. OX40 is differentially expressed on activated rat and mouse T cells and is the sole receptor for the OX40 ligand.
al-Shamkhani A; Birkeland ML; Puklavec M; Brown MH; James W; Barclay AN
Eur J Immunol; 1996 Aug; 26(8):1695-9. PubMed ID: 8765008
[TBL] [Abstract][Full Text] [Related]
5. Activated T cells express the OX40 ligand: requirements for induction and costimulatory function.
Mendel I; Shevach EM
Immunology; 2006 Feb; 117(2):196-204. PubMed ID: 16423055
[TBL] [Abstract][Full Text] [Related]
6. Contribution of OX40/OX40 ligand interaction to the pathogenesis of rheumatoid arthritis.
Yoshioka T; Nakajima A; Akiba H; Ishiwata T; Asano G; Yoshino S; Yagita H; Okumura K
Eur J Immunol; 2000 Oct; 30(10):2815-23. PubMed ID: 11069062
[TBL] [Abstract][Full Text] [Related]
7. Identification of rat OX40 ligand by molecular cloning.
Akiba H; Atsuta M; Yagita H; Okumura K
Biochem Biophys Res Commun; 1998 Oct; 251(1):131-6. PubMed ID: 9790919
[TBL] [Abstract][Full Text] [Related]
8. Consequences of OX40-OX40 ligand interactions in langerhans cell function: enhanced contact hypersensitivity responses in OX40L-transgenic mice.
Sato T; Ishii N; Murata K; Kikuchi K; Nakagawa S; Ndhlovu LC; Sugamura K
Eur J Immunol; 2002 Nov; 32(11):3326-35. PubMed ID: 12555678
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic effect of anti-OX40L and anti-TNF-alpha MAbs in a murine model of chronic colitis.
Totsuka T; Kanai T; Uraushihara K; Iiyama R; Yamazaki M; Akiba H; Yagita H; Okumura K; Watanabe M
Am J Physiol Gastrointest Liver Physiol; 2003 Apr; 284(4):G595-603. PubMed ID: 12631559
[TBL] [Abstract][Full Text] [Related]
10. Functional characterization of OX40 expressed on human CD8+ T cells.
Fujita T; Ukyo N; Hori T; Uchiyama T
Immunol Lett; 2006 Jul; 106(1):27-33. PubMed ID: 16750861
[TBL] [Abstract][Full Text] [Related]
11. Roles of OX40 in the development of murine experimental allergic conjunctivitis: exacerbation and attenuation by stimulation and blocking of OX40.
Fukushima A; Yamaguchi T; Ishida W; Fukata K; Yagita H; Ueno H
Invest Ophthalmol Vis Sci; 2006 Feb; 47(2):657-63. PubMed ID: 16431965
[TBL] [Abstract][Full Text] [Related]
12. Expression of tumour necrosis factor (TNF) ligand superfamily co-stimulatory molecules CD30L, CD27L, OX40L, and 4-1BBL in murine hearts with acute myocarditis caused by Coxsackievirus B3.
Seko Y; Takahashi N; Oshima H; Shimozato O; Akiba H; Takeda K; Kobata T; Yagita H; Okumura K; Azuma M; Nagai R
J Pathol; 2001 Dec; 195(5):593-603. PubMed ID: 11745696
[TBL] [Abstract][Full Text] [Related]
13. Blockade of the OX40 ligand prolongs corneal allograft survival.
Hattori T; Usui Y; Okunuki Y; Sonoda Y; Usui M; Takada E; Mizuguchi J; Yagita H; Okumura K; Akiba H; Takeuchi M
Eur J Immunol; 2007 Dec; 37(12):3597-604. PubMed ID: 18022861
[TBL] [Abstract][Full Text] [Related]
14. Requirements for the functional expression of OX40 ligand on human activated CD4+ and CD8+ T cells.
Kondo K; Okuma K; Tanaka R; Zhang LF; Kodama A; Takahashi Y; Yamamoto N; Ansari AA; Tanaka Y
Hum Immunol; 2007 Jul; 68(7):563-71. PubMed ID: 17584577
[TBL] [Abstract][Full Text] [Related]
15. The adjuvancy of OX40 ligand (CD252) on an HIV-1 canarypox vaccine.
Liu J; Ngai N; Stone GW; Yue FY; Ostrowski MA
Vaccine; 2009 Aug; 27(37):5077-84. PubMed ID: 19573639
[TBL] [Abstract][Full Text] [Related]
16. Contribution of CD30/CD153 but not of CD27/CD70, CD134/OX40L, or CD137/4-1BBL to the optimal induction of protective immunity to Mycobacterium avium.
Flórido M; Borges M; Yagita H; Appelberg R
J Leukoc Biol; 2004 Nov; 76(5):1039-46. PubMed ID: 15316035
[TBL] [Abstract][Full Text] [Related]
17. Expression of tumour necrosis factor (TNF) receptor/ligand superfamily co-stimulatory molecules CD40, CD30L, CD27L, and OX40L in murine hearts with chronic ongoing myocarditis caused by coxsackie virus B3.
Seko Y; Takahashi N; Oshima H; Shimozato O; Akiba H; Kobata T; Yagita H; Okumura K; Azuma M; Yazaki Y
J Pathol; 1999 Aug; 188(4):423-30. PubMed ID: 10440754
[TBL] [Abstract][Full Text] [Related]
18. B7.1 immunogene therapy effectively activates CD(4+) tumor-infiltrating lymphocytes in the central nervous system in comparison with B7.2 gene therapy.
Ando H; Saio M; Ohe N; Tamakawa N; Yu H; Nakayama T; Yoshimura S; Kaku Y; Iwama T; Shinoda J; Sakai N; Takami T
Int J Oncol; 2002 Apr; 20(4):807-12. PubMed ID: 11894129
[TBL] [Abstract][Full Text] [Related]
19. OX40-OX40 ligand interaction in T-cell-mediated immunity and immunopathology.
Ishii N; Takahashi T; Soroosh P; Sugamura K
Adv Immunol; 2010; 105():63-98. PubMed ID: 20510730
[TBL] [Abstract][Full Text] [Related]
20. Anti-tumour therapeutic efficacy of OX40L in murine tumour model.
Ali SA; Ahmad M; Lynam J; McLean CS; Entwisle C; Loudon P; Choolun E; McArdle SE; Li G; Mian S; Rees RC
Vaccine; 2004 Sep; 22(27-28):3585-94. PubMed ID: 15315837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
